You are here: Welcome to the MPKB » Welcome to the MPKB » Diseases » Cancer
Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
Next revisionBoth sides next revision
home:diseases:cancer [03.13.2019] – [Recent research] sallieqhome:diseases:cancer [03.13.2019] – [H] sallieq
Line 203: Line 203:
 Note also that the primary ARBs being evaluated, candesartan and telmisartan, have significantly different actions than olmesartan. According to the //in silico// emulations of Dr. Marshall, they are VDR antagonists. Note also that the primary ARBs being evaluated, candesartan and telmisartan, have significantly different actions than olmesartan. According to the //in silico// emulations of Dr. Marshall, they are VDR antagonists.
  
-==== H ====+==== Risk ====
  
 <blockquote>analyses found no evidence that cancer risk increased with increasing duration of ARB exposure (RR increase per year=0.99) <blockquote>analyses found no evidence that cancer risk increased with increasing duration of ARB exposure (RR increase per year=0.99)
Line 346: Line 346:
 Olmesartan and Bay11-7082 inhibit the MCF-7 cells growth indicating RAS and NF-kappaB pathway blockade lead to cytotoxicity and apoptosis induction against tumour cells. So ARBs and NF-kappaB pathway inhibitors could be considered as anticancer drugs in future.  (({{pubmed>long:26138656}})) Olmesartan and Bay11-7082 inhibit the MCF-7 cells growth indicating RAS and NF-kappaB pathway blockade lead to cytotoxicity and apoptosis induction against tumour cells. So ARBs and NF-kappaB pathway inhibitors could be considered as anticancer drugs in future.  (({{pubmed>long:26138656}}))
  
 +In this large population-based gastro-oesophageal cancer cohort, we found moderately reduced cancer-specific mortality among ARB users. However, confirmation in further independent epidemiological studies with sufficient staging information is required.  (({{pubmed>long:29105106}}))
  
 +miR-205 mediates the inhibition of cervical cancer cell proliferation using olmesartan.  (({{pubmed>long:    28304186}}))
  
-In this large population-based gastro-oesophageal cancer cohort, we found moderately reduced cancer-specific mortality among ARB users. However, confirmation in further independent epidemiological studies with sufficient staging information is required.  (({{pubmed>long:29105106}})) 
  
 Vitamin D and immune cells stimulate bone marrow disease (({{pubmed>long:30718230}}))  Vitamin D and immune cells stimulate bone marrow disease (({{pubmed>long:30718230}})) 
home/diseases/cancer.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.